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Strong evidence of linkage to late-onset Alzheimer disease (LOAD) has been observed on chromosome 10, which
implicates a wide region and at least one disease-susceptibility locus. Although signiﬁcant associations with several
biological candidate genes on chromosome 10 have been reported, these ﬁndings have not been consistently rep-
licated, and they remain controversial. We performed a chromosome 10–speciﬁc association study with 1,412 gene-
based single-nucleotide polymorphisms (SNPs), to identify susceptibility genes for developing LOAD. The scan
included SNPs in 677 of 1,270 known or predicted genes; each gene contained one or more markers, about half
(48%) of which represented putative functional mutations. In general, the initial testing was performed in a white
case-control sample from the St. Louis area, with 419 LOAD cases and 377 age-matched controls. Markers that
showed signiﬁcant association in the exploratory analysis were followed up in several other white case-control
sample sets to conﬁrm the initial association. Of the 1,397 markers tested in the exploratory sample, 69 reached
signiﬁcance ( ). Five of these markers replicated at in the validation sample sets. Onemarker, rs498055,P ! .05 P ! .05
located in a gene homologous to RPS3A (LOC439999), was signiﬁcantly associated with Alzheimer disease in four
of six case-control series, with an allelic P value of .0001 for a meta-analysis of all six samples. One of the case-
control samples with signiﬁcant association to rs498055 was derived from the linkage sample ( ). ThesePp .0165
results indicate that variants in the RPS3A homologue are associated with LOAD and implicate this gene, adjacent
genes, or other functional variants (e.g., noncoding RNAs) in the pathogenesis of this disorder.
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Alzheimer disease (AD [MIM 104300]) is the most sig-
niﬁcant cause of dementia in developed countries and
is clinically characterized by memory loss of subtle on-
set followed by a slowly progressive dementia that has
a course of several years. The risk of AD has a genetic
component, as evidenced by an increased risk of AD
among ﬁrst-degree relatives of affected individuals. So far,
three genes have been identiﬁed that lead to the rare au-
tosomal dominant early-onset form of AD. Mutations in
the three genes—b-amyloid precursor protein (APP [MIM
104760]) (Goate et al. 1991), presenilin 1 (PSEN1 [MIM
104311]) (Sherrington et al. 1995), and presenilin 2
(PSEN2 [MIM 600759]) (Levy-Lahad et al. 1995)—lead
to an increase in the production of long amyloid b peptide
(Ab42), the main component in amyloid plaques. The
great majority of AD cases are of late onset (age at onset
165 years) and show complex, non-Mendelian patterns
of inheritance. Late-onset AD (LOAD [MIM 606626])
probably results from the combined effects of variation
in a number of genes as well as from environmental fac-
tors. Early genetic studies of LOAD demonstrated that
the 4 variant ofAPOE (MIM 107741) is associatedwith
increased risk of LOAD and with lower age at disease
onset in a dose-dependent manner (Corder et al. 1993).
Genomewide linkage screens in patients with LOAD
have identiﬁed several other chromosomal regions (re-
viewed by Pastor and Goate [2004]), implying that ge-
netic risk factors other than APOE must exist. Putative
LOAD-susceptibility loci on chromosomes 9, 10, and 12
have been reported in two or more sample sets by dif-
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Figure 1 Allelic P values of 1,397 exploratory markers from the
exploratory sample (middle), with a bar graph showing the distribution
of annotated genes across chromosome 10 (bottom).Marker rs498055
is noted with an arrow, and a P value of .05 is marked with a line.
The previously identiﬁed linkage peak regions are noted with solid
lines and references (top). Studies with multipoint LOD scores 12 in
white samples were included. Results of single-marker studies were
not included.
ferent groups (Pericak-Vance et al. 1997, 2000; Rogaeva
et al. 1998; Kehoe et al. 1999; Myers et al. 2000, 2002;
Blacker et al. 2003). Perhaps the most prominent among
them is the linkage to chromosome 10, observed in a
number of nonoverlapping samples from studies em-
ploying distinct approaches, including linkage analysis
based on a genomewide screen, a candidate gene–based
limited genome screen, and a genome screen that used
plasma Ab levels as a quantitative phenotype (Kehoe et
al. 1999; Bertram et al. 2000; Ertekin-Taner et al. 2000;
Myers et al. 2000; Blacker et al. 2003; Farrer et al.
2003). Several candidate genes that are under or near
the chromosome 10 linkage peaks have been tested for
association with LOAD, but none has been consistently
replicated (Alzheimer Disease Forum).
To identify the genes and mutations for LOAD, we
undertook a screen of putative functional SNPs in 677
genes under the linkage peak, using a powerful set of
unrelated cases and controls. A similar approach was
used to identify the glyceraldehyde-3-phosphate dehy-
drogenase gene (GAPD [MIM 138400]), located on the
short arm of chromosome 12, as a putative LOAD risk
gene (Li et al. 2004). Here, we report the ﬁndings from
this scan of 1,412 SNPs on chromosome 10.
Material and Methods
Sample-Set Characteristics
Three white clinical case-control series were used in this study:
(1) the WU series (422 cases; 382 controls), collected through
the Washington University Alzheimer’s Disease Research Cen-
ter (ADRC) patient registry; (2) the UK series (368 cases; 404
controls), collected as part of the Medical Research Council
(MRC) Late-Onset ADGenetic Resource, including those from
the Cardiff UniversityWales School ofMedicine and fromKing’s
College London; and (3) the UCSD series (217 cases; 409 con-
trols), collected through the ADRC of the University of Cal-
ifornia–San Diego. In total, 1,007 AD cases and 1,195 controls
were analyzed. Cases in these series had received a clinical
diagnosis of dementia of the Alzheimer type (DAT), with use
of criteria equivalent to NINCDS-ADRDA (National Insti-
tute of Neurological and Communicative Diseases and Stroke/
Alzheimer’s Disease and Related Disorders Association) (Mc-
Khann et al. 1984) but modiﬁed slightly to include AD as a
diagnosis for individuals aged 190 years (Berg et al. 1998).
The minimum age at onset of DAT was 60 years. Controls
were nondemented individuals aged 160 years at assessment
who were screened for dementia through use of neuropsycho-
logical tests and clinical interviews. Controls were matched
with cases for age and sex. These samples all show an expected
age and APOE 4–genotype distribution and do not appear
to have evidence of population stratiﬁcation (Li et al. 2004).
More-detailed information about these samples can be found
elsewhere (Li et al. 2005).
A fourth case-control series was generated by selecting one
case per family from our genetic linkage sample (Myers et al.
2002) and matching each of them to an equal number of white,
nondemented controls collected in St. Louis (these controls are
independent of the controls used in the exploratory sample
above). There were 429 cases and 321 controls in this series
(mean age at onset for the case series is 73.6 years; mean age
at assessment for controls is 75.0 years). The linkage pedigrees
from the National Institute of Mental Health (NIMH) series
and the NIA series (292 pedigrees; 624 affected individuals)
(Myers et al. 2002) were also genotyped for the single SNP
signiﬁcant in all case-control series.
Two small series that consisted of neuropathologically con-
ﬁrmed white cases and controls were derived from the U.S.
ADRCs (contributing centers are listed in the Acknowledg-
ments) and from Newcastle upon Tyne, United Kingdom. Of
the samples in the U.S. series, 40% were assessed as being at
either Braak and Braak stage 5 or 6 (cases) or Braak stage 2
or less (controls). The remaining samples (cases) met neuro-
pathological criteria for AD. Both the controls and cases were
selected to be largely free of such complicating pathologies as
Lewy bodies and vascular events. The combined series included
360 cases (age range 65–97 years; 220 women) and 252 con-
trols (age range 65–100 years; 123 women).
SNP Selection and Genotyping
Genotyping of all samples was performed with written in-
formed consent/assent from the participating individuals and
their caregivers and approval from the participating institu-
tions. Polymorphisms used for genotyping were identiﬁed from
either the Celera human genome database that includes pub-
licly available SNP data or the Applera Genome Sequencing
Initiative database. For this study, we chose gene-based SNPs,
with a preference for putative functional mutations, as pre-
dicted in the Celera or public SNP databases, with the aim to
screen as many predicted genes with at least one variant as
possible (table A1 and ﬁg. A1 [online only]). Thus, these SNPs
consist of 367 missense/nonsense mutations, 1 donor splice-
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Figure 2 Allelic P values of markers around the RPS3A homologue region (LOC43999) in both exploratory and validation samples,
along with a gene map of the region and Celera assembly coordinates (in Mbp). Blue diamonds indicate two-sided explatory sample P values;
the other symbols indicate one-sided replication sample P values for WU (red squares), UCSD (gray triangles), and UK (green circle).
site variant, 172 putative transcription factor binding site mu-
tations, 9 exon-skipping site variants, 109 variants in the UTR,
and 739 variants of other types (intronic, silent, and unknown
types [SNPs of unknown and silent types were annotated as
functional variants in previous genome assemblies]). They cover
a total of 677 of 1,270 annotated genes on chromosome 10.
All genomic positions for all SNPs and genes are from the
Celera Genome Assembly R27. All SNPs had a minor-allele
frequency (MAF) of 12% in either cases or controls. TheMAF
was 2%–5% for 80 exploratory markers and 5%–10% for
165 markers. The remaining markers had MAFs of 10%–
50%, with approximately equal numbers of SNPs in each 10%
interval.
Genotyping of SNPs was undertaken by allele-speciﬁc real-
time PCR for individual samples, by use of primers designed
and validated in-house (Germer et al. 2000). Cases and con-
trols were always run on the same plate in a blind fashion.
Assay quality was scored by an individual who had no access
to the sample phenotypes, before the genotyping results were
subjected to statistical analysis. Overall, the accuracy of our
genotyping was 199%, as determined by internal comparisons
of differentially designed assays for the same marker and by
comparisons of the same marker across different groups.
Genotyping was performed in stages—markers were ﬁrst
genotyped in one sample set, the exploratory set. Generally,
the WU sample set was used as the exploratory sample set.
However, when markers were tested for replication in another
sample set, we also genotyped that sample set with novel assays
that had passed our assay-validation step. Overall, we used
the UK sample (105 assays) and the UCSD sample (1 assay)
as exploratory sets for !8% of all tested assays. Signiﬁcant
exploratory markers ( ) were then genotyped in two ad-P ! .05
ditional clinical case-control series. After replication in at least
one of these other sample sets, additional ﬁne-mapping mark-
ers were genotyped near the replicated SNPs. When additional
assays for markers near signiﬁcant exploratory markers were
immediately available, they were genotyped in the exploratory
sample in parallel with attempting to replicate in the validation
samples. Signiﬁcant markers were followed up as described
above. Five SNPs that showed some level of replication in one
or both of the additional case-control series were genotyped
in a case-control series derived from the families originally used
for our genomewide linkage scan. One of these SNPs (rs498055)
was also genotyped in the case-control series that was com-
posed of neuropathologically conﬁrmed AD cases and controls.
Statistical Analysis
To help exclude assays with possible genotyping errors from
the analysis, Hardy-Weinberg equilibrium tests were ﬁrst per-
formed in both the case and the control samples. Assays with
signiﬁcant deviation fromHardy-Weinberg equilibrium in con-
trols were then examined for genotyping quality ( ; 63P ! .05
markers in the exploratory stage). As a result, two assays were
dropped from our analysis. One remaining assay with anMAF
!10% was signiﬁcant in the exploratory set but did not validate
in the other sample sets andwas inHardy-Weinberg equilibrium.
Pearson’s x2 test was used to calculate P values for the as-
sociation of an allele with disease status within a single study.
This test of association was performed on the basis of the fre-
quency counts of a contingency table of allele and disease2# 2
status. Two-sided P values are presented for the exploratory
study. In the validation stage, one-sided P values were calcu-
lated if the odds ratios (ORs) were in the direction observed
in the exploratory stage. P values were not adjusted for mul-
tiple comparisons unless otherwise stated. ORs and the 95%
CIs for an allelic effect were also estimated. ORs and P values
for meta-analyses that combine results of multiple sample sets
were calculated using the Cochran-Mantel-Haenszel test, and
were controlled for the sample set (Agresti 1990). Evidence of
Ta
bl
e
1
A
lle
lic
Te
st
s
of
R
ep
lic
at
ed
M
ar
ke
rs
an
d
LO
A
D
M
A
R
K
E
R
,
G
E
N
E
,
PO
SI
T
IO
N
(b
p)
A
N
D
SA
M
P
L
E
C
A
SE
S
C
O
N
T
R
O
L
S
M
A
F
(%
)
P
O
R
(C
Ia
)
PO
W
E
R
T
O
R
E
P
L
IC
A
T
E
N
o.
w
it
h
G
en
ot
yp
e
M
A
F
(%
)
N
o.
w
it
h
G
en
ot
yp
e
11
12
22
To
ta
l
11
12
22
To
ta
l
rs
10
57
97
1,
P
C
G
F5
,
86
73
34
01
:
W
U
b
2
54
36
3
41
9
6.
9
0
33
34
4
37
7
4.
4
.0
29
1.
62
(1
.0
5–
.5
2)
…
U
C
SD
c
2
33
21
3
24
8
7.
5
2
37
36
0
39
9
5.
1
.0
44
1.
49
(1
.0
1–
.1
9)
.6
1
U
K
c
1
39
30
7
34
7
5.
9
3
32
34
5
38
0
5.
0
.2
2
1.
19
(.
82
–.
75
)
.6
6
U
C
SD
an
d
U
K
c
3
72
52
0
59
5
6.
6
5
69
70
5
77
9
5.
1
.0
42
1.
33
(1
.0
1–
.7
4)
.8
8
A
ll
5
12
6
88
3
1,
01
4
6.
7
5
10
2
1,
04
9
1,
15
6
4.
8
.0
06
8
1.
43
(1
.1
0–
.8
5)
…
rs
49
80
55
,
L
O
C
43
99
99
,9
10
96
11
1:
U
K
b
80
17
5
92
34
7
48
.3
67
19
4
12
4
38
5
42
.6
.0
29
1.
26
(1
.0
2–
.5
5)
…
U
C
SD
c
64
10
7
48
21
9
53
.7
85
15
6
10
2
34
3
47
.5
.0
22
1.
28
(1
.0
4–
.5
6)
.5
9
W
U
c
12
5
17
5
89
38
9
54
.6
65
20
0
86
35
1
47
.0
.0
01
7
1.
36
(1
.1
4–
.6
1)
.7
1
U
C
SD
an
d
W
U
c
18
9
28
2
13
7
60
8
54
.3
15
0
35
6
18
8
69
4
47
.3
.0
00
21
1.
32
(1
.1
6–
.5
1)
.8
9
A
ll
26
9
45
7
22
9
95
5
52
.1
21
7
55
0
31
2
1,
07
9
45
.6
.0
00
04
1.
3
(1
.1
5–
.4
7)
…
rs
44
17
20
6,
A
L
D
H
18
A
1,
91
13
76
78
:
U
K
b
36
15
3
15
8
34
7
32
.4
61
16
9
15
4
38
4
37
.9
.0
29
.7
9
(.
63
–.
98
)
…
U
C
SD
c
17
10
2
10
1
22
0
30
.9
50
15
7
14
2
34
9
36
.8
.0
21
.7
7
(.
62
–.
95
)
.5
9
W
U
c
45
15
5
19
0
39
0
31
.4
38
16
5
14
8
35
1
34
.3
.1
2
.8
8
(.
73
–.
05
)
.7
1
U
C
SD
an
d
W
U
c
62
25
7
29
1
61
0
31
.2
88
32
2
29
0
70
0
35
.6
.0
13
.8
3
(.
72
–.
95
)
.9
0
A
ll
98
41
0
44
9
95
7
31
.7
14
9
49
1
44
4
1,
08
4
36
.4
.0
01
9
.8
1
(.
71
–.
93
)
…
rs
60
08
79
,
SO
R
C
S1
,
10
26
62
20
0:
W
U
b
6
87
32
5
41
8
11
.8
4
54
31
9
37
7
8.
2
.0
17
1.
5
(1
.0
7–
.0
9)
…
U
C
SD
c
3
42
19
6
24
1
10
.0
6
53
33
5
39
4
8.
2
.1
5
1.
23
(.
89
–.
71
)
.6
7
U
K
c
6
66
27
7
34
9
11
.2
3
63
31
9
38
5
9.
0
.0
79
1.
28
(.
96
–.
70
)
.7
4
U
C
SD
an
d
U
K
c
9
10
8
47
3
59
0
10
.7
9
11
6
65
4
77
9
8.
6
.0
40
1.
26
(1
.0
1–
.5
6)
.9
2
A
ll
15
19
5
79
8
1,
00
8
11
.2
13
17
0
97
3
1,
15
6
8.
5
.0
04
3
1.
34
(1
.1
0–
.6
5)
…
rs
19
03
90
8,
hC
G
20
39
14
0,
10
29
40
84
3:
W
U
b
14
97
30
8
41
9
14
.9
5
77
29
4
37
6
11
.6
.0
50
1.
34
(1
.0
0–
.8
0)
…
U
C
SD
c
6
54
18
8
24
8
13
.3
2
81
31
4
39
7
10
.7
.0
79
1.
28
(.
96
–.
71
)
.5
3
U
K
c
11
78
24
7
33
6
14
.9
10
76
29
6
38
2
12
.6
.1
0
1.
22
(.
94
–.
57
)
.5
7
U
C
SD
an
d
U
K
c
17
13
2
43
5
58
4
14
.2
12
15
7
61
0
77
9
11
.6
.0
29
1.
24
(1
.0
3–
.5
0)
.8
0
A
ll
31
22
9
74
3
1,
00
3
14
.5
17
23
4
90
4
1,
15
5
11
.6
.0
07
0
1.
28
(1
.0
7–
.5
3)
…
a
95
%
C
I
fo
r
ex
pl
or
at
or
y
an
d
to
ta
l
sa
m
pl
es
;
90
%
C
I
fo
r
va
lid
at
io
n
sa
m
pl
es
.
b
E
xp
lo
ra
to
ry
sa
m
pl
e
se
t.
c
V
al
id
at
io
n
sa
m
pl
e
se
t:
on
e-
si
de
d
P
va
lu
e.
82 The American Journal of Human Genetics Volume 78 January 2006 www.ajhg.org
Table 2
Allelic Association in Linkage Case-Control Series
MARKER
LOCATION
(Mb)
NO. OF CASES
WITH GENOTYPE
NO. OF
CONTROLS
WITH GENOTYPE
Pa OR (95% CI)11 12 22 11 12 22
rs1057971 86.7 1 35 304 0 41 302 .73 .91 (.57–1.43)
rs498055 91.09 110 207 112 58 162 96 .017 1.26 (1.02–1.54)
rs4417206 91.13 45 163 145 59 139 131 .24 .87 (.70–1.09)
rs600879 102.66 285 62 6 275 56 8 1 1.01 (.72–1.43)
rs1903908 102.94 13 87 265 6 84 252 .45 1.12 (.84–1.51)
NOTE.—For cases, one affected sibling was genotyped from each family in the linkage sample
(Myers et al. 2002) and was compared with a set of independent controls.
a Allelic tests are two sided except for rs498055.
Table 3
Linkage Analysis of Pedigrees Stratiﬁed by rs498055
Sample No. of Pedigrees No. Affected Peak LOD
Location
(cM)
All 343 733 3.84 68
Pedigrees with SNPs 292 624 3.18 68
Probands with A 228 488 3.37 68
Probands with G 221 471 2.38 50
Probands without A 64 136 .73 90
Probands without G 71 153 1.18 67
replication, rather than multiple testing corrections, was used
to evaluate the signiﬁcance of associated SNPs.
Linkage Analysis
To determine whether rs498055 contributed to our linkage
signal on chromosome 10, we stratiﬁed families on the basis
of the presence or absence of the risk allele of rs498055 in the
proband of each family. The families used in this analysis were
the NIMH and the National Cell Repository for Alzheimer’s
Disease families from our linkage screen (Myers et al. 2002).
The analysis was performed in Mapmaker/SIBS (“All pairs,
UNWEIGHTED”). For the “proband” analysis, the (numer-
ically) ﬁrst individual with the SNP genotype was identiﬁed as
the proband.
Haplotype Analysis
Several studies have shown that placing individual SNPs into
the context of a haplotype increases biological information
(Balciuniene et al. 2002; Knoblauch et al. 2002; Van Eerdew-
egh et al. 2002). Similarly, placing haplotypes into their evo-
lutionary context also increases biological information (Tem-
pleton et al. 2005). For the haplotype analysis, we used SNPs
that were typed in all three series and were located within ∼40
kb of rs498055. These criteria resulted in a data set of 11
SNPs in 1,159 controls and 974 cases from the WU, UK, and
UCSD case-control samples.
Haplotypes were estimated using the software PHASE (Ste-
phens et al. 2001; Stephens and Donnelly 2003). A set of 95%-
plausible haplotype trees was estimated using statistical par-
simony in the program TCS (Clement et al. 2000; Templeton
et al. 2000).
Association with LOAD was tested by tree scanning (Tem-
pleton et al. 2005), which was modiﬁed tomanage case-control
data (Nowotny et al. 2005). A tree scan uses the haplotype
network to deﬁne tests that are based on each branch of the
tree. Each branch represents an a priori deﬁned pooling of
haplotypes: haplotypes on one side of the branch are pooled
together and deﬁne an allele, whereas the haplotypes on the
other side are pooled to deﬁne a separate allele. This results
in a biallelic locus that can be tested for association with the
phenotype. A permutation-based analog of the sequential Bon-
ferroni (Westfall and Young 1993) was used to obtain nominal
and multiple-test–corrected signiﬁcance values with the para-
metric P value used as the test statistic. This permutationmethod
takes into account the correlation structure between tests while
correcting for multiple tests.
Results
To identify genetic variation associated with LOAD on
chromosome 10, we performed a SNP-based association
study with three well-characterized LOAD case-control
series. Our strategy was to test markers in one sample
set (exploratory sample) and to follow up signiﬁcant
markers in the two remaining sample sets (validation
samples). Using this paradigm, we ﬁrst scanned a rela-
tively large number of gene-based putative functional
SNPs across chromosome 10, with the highest SNP den-
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Figure 3 Haplotype networks. Each oval contains the haplotype identiﬁcation number, the state at each locus, and the number of times
it was inferred to occur in this sample set. To simplify the presentation of the network, haplotypes that appear only once in the sample are not
shown, and selected haplotypes have been collapsed. The branch that was signiﬁcant in the tree scan is denoted by the dashed line. P values
for the original and conditional analyses are also provided. Mutations at rs498055 are indicated by “TRrC”; the mutation at rs495998 is
indicated by “ARrC.”
sity in regions directly under the linkage peak reported
above. Signiﬁcant markers were then genotyped in the
other two sample sets to attempt replication of the initial
association. Regions with markers showing strong asso-
ciation with the exploratory sample and replication in at
least one other sample set were then tested with addi-
tional markers. Speciﬁcally, we genotyped a total of 1,397
SNPs by allele-speciﬁc PCR in the exploratory stage (ﬁg.
1), targeting 674 genes. From these, we genotyped 408
genes with 1 marker, 141 with 2 markers, 57 with 3
markers, 47 with 4–7 markers, and the remainder with
8markers. Themajority of exploratorymarkers (1,291)
were tested in the WU sample set. In the UK sample set,
105 markers were genotyped, and 1 marker was ge-
notyped in the UCSD sample set. Of the 1,397 tested
SNPs, 69 were signiﬁcantly associated with LOAD in
the exploratory sample ( ). These markers wereP ! .05
scattered across the chromosome, as would be expected
because of the high probability of false-positive associ-
ations due to the large number of SNPs analyzed (ﬁg.
1). We subsequently genotyped the 69 markers in the
two validation sample sets and found 5 that replicated
in a meta-analysis combining the two validation sample
sets (one-sided ) (table 1). One marker, rs498055,P ! .05
located in LOC439999, a gene with high homology
to RPS3A (MIM 180478), was signiﬁcant ( ) inP ! .05
each of the three sample sets and was the most signiﬁ-
cant ( ) marker in the three-sample meta-Pp .00004
analysis (table 1). One other marker, rs4417206, lo-
cated in a neighboring gene ALDH18A1 (or PYCS
[MIM 138250]), was also signiﬁcant in the combined
validation study ( ). Markers rs4417206 inPp .013
ALDH18A1 and rs498055 in LOC439999 are ∼41 kb
apart and are in strong linkage disequilibrium (LD) with
one another ( ; ).′ 2D p 0.98 r p 0.43
To determine whether any of the ﬁve SNPs that rep-
licated in the meta-analysis (rs1057971, rs498055,
rs4417206, rs600879, and rs1903908) were also asso-
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Table 4
Measures of Pairwise D′ and in UK Controls2r
Marker Distance rs500470 rs533383 rs533343 rs11594687 rs7895441 rs495998 rs17110999 rs7906450 rs498055 rs2296690
rs500470 .00 1.00 1.00 1.00 1.00 .89 1.00 1.00 .88 .95
rs533383 5.78 .99 .99 1.00 1.00 .89 1.00 1.00 .88 .95
rs533343 .01 .74 .73 1.00 .66 .99 1.00 .92 .98 1.00
rs11594687 4.03 .07 .07 .05 1.00 1.00 1.00 1.00 1.00 1.00
rs7895441 1.40 .37 .37 .22 .03 1.00 1.00 .94 .98 1.00
rs495998 5.76 .54 .54 .48 .11 .25 1.00 1.00 .99 .77
rs17110999 2.17 .26 .27 .36 .02 .72 .18 1.00 1.00 1.00
rs7906450 5.57 .28 .28 .32 .02 .68 .19 .94 1.00 .85
rs498055 1.49 .52 .51 .47 .11 .24 .98 .18 .19 .78
rs2296690 16.03 .09 .09 .07 .69 .04 .10 .03 .02 .10
rs1804934 .20 .04 .04 .05 .00 .00 .02 .00 .00 .02 .00
rs749049 4.96 .01 .01 .00 .10 .06 .11 .19 .20 .11 .11
hDV68531050 .02 .06 .06 .02 .00 .18 .04 .01 .01 .04 .00
rs2986401 6.55 .03 .03 .04 .05 .19 .00 .33 .30 .00 .07
rs2275272 5.51 .09 .09 .07 .74 .03 .09 .02 .03 .09 .94
rs4417206 8.31 .30 .29 .21 .05 .11 .44 .08 .09 .43 .07
rs11188410 .09 .14 .13 .19 .01 .01 .10 .00 .00 .09 .01
rs10882645 7.81 .03 .03 .03 .05 .17 .00 .31 .33 .00 .06
hDV68531048 12.0 .06 .06 .02 .00 .18 .04 .01 .01 .04 .00
rs11553577 37.1 .14 .13 .19 .01 .00 .09 .00 .00 .08 .02
hCV25943811 .24 .06 .06 .02 .00 .18 .04 .01 .01 .04 .00
rs1418709 65.0 .00 .00 .02 .11 .18 .05 .12 .13 .05 .15
NOTE.—Measures of pairwise D′ are shown above the diagonal; values are shown below the diagonal.2r
ciated with risk for LOAD in our original linkage study
sample (Myers et al. 2002), we genotyped the entire
series and performed two analyses. First, we used a case-
control approach by selecting one case (proband) per
family, and wematched each of them to an equal number
of unrelated controls. We chose to use a case-control
analysis rather than a discordant–sib-pair analysis be-
cause of the greater power in the case-control design and
because discordant siblings were available for only a
proportion of the cases. A one-sided x2 test demonstrated
signiﬁcant evidence of association in the case-control
sample with the same allele as in the other case-control
series for rs498055 ( ); all other SNPs failedPp .0165
to show any evidence of association (table 2). The ORs
observed in the linkage series for rs498055 were simi-
lar to those observed in the other case-control series
( ; 95% CI 1.02–1.54).ORp 1.26
Marker rs498055 was also examined in two small
series (183 cases/127 controls; 160 cases/106 controls)
of neuropathologically conﬁrmed cases and controls. The
SNP was not associated with AD risk in these samples
( and , respectively). However, power toPp .63 Pp .21
replicate our ﬁnding in these samples was low (40% and
36%, respectively; 60% power in the combined sample
sets).
To further estimate the effect of rs498055 in the link-
age sample, we performed a stratiﬁed linkage analysis
of the stage II linkage data, on the basis of the genotype
of the proband of each pedigree. We performed stratiﬁed
linkage analyses using the pedigrees in which the pro-
band had a copy of allele A and pedigrees in which the
proband had a copy of allele G (table 3). We also con-
sidered pedigrees in which the proband was a homozy-
gote for the A allele and in which the proband was a
homozygote for the G allele. The results did not show
an increase in LOD score in probands with the risk allele.
In fact, although the ﬁrst two groups were roughly the
same size, the LOD score was substantially smaller in
pedigrees in which the proband had a copy of the risk
allele. This suggests that the rs498055 polymorphism
(at 91.1 Mb) may have little direct effect on the linkage
ﬁndings, which have their peak near D10S1211 (at 59.9
Mb), and that other loci contributing to disease have yet
to be found in this region.
These ﬁndings prompted us to focus further follow-
up on the region ﬂanking these two genes. A total of 53
markers, covering a 1.49-Mb region, were typed in the
exploratory sample, and association of these SNPs was
examined. Ten of the markers resulted in a P value !.1
in the exploratory sample, and ﬁve were signiﬁcant at
(ﬁg. 2). After genotyping these markers in theP ! .05
validation samples, rs498055 remained the only marker
that was signiﬁcantly associated with LOAD in each of
the three sample sets.
We examined LD structure in this region, using ge-
notypes from the UK and the WU sample sets. We ob-
served a block of high LD extending from rs500470
to rs1418709, covering at least 190 kb of the ge-
nomic region that includes the most-signiﬁcant markers,
rs498055 and rs4417206.Although theD′ values among
neighboring SNPs were high, the values were generally2r
low (table 4). The LD structure was comparable between
cases and controls. The ﬁve signiﬁcant markers with a
P value !.05 (rs500470, rs533343, rs495998, rs498055,
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rs1804934 rs749049 hDV68531050 rs2986401 rs2275272 rs4417206 rs11188410 rs10882645 hDV68531048 rs11553577 hCV25943811 rs1418709
1.00 .12 .92 .20 1.00 .98 1.00 .18 .92 .96 .92 .02
1.00 .11 .92 .20 1.00 .98 .96 .19 .92 .93 .92 .03
1.00 .04 1.00 .19 1.00 .98 1.00 .16 1.00 .97 1.00 .20
.68 1.00 .05 1.00 1.00 1.00 1.00 1.00 .05 1.00 .05 1.00
.76 .50 .95 .63 1.00 1.00 .62 .60 .95 .25 .95 .88
1.00 .37 .91 .09 .76 .99 1.00 .09 .91 .94 .91 .23
.16 1.00 1.00 .96 1.00 1.00 .26 .94 1.00 .04 1.00 .86
.27 1.00 1.00 .90 1.00 1.00 .39 .95 1.00 .17 1.00 .87
1.00 .37 .91 .08 .77 .98 .94 .08 .91 .89 .91 .23
1.00 .87 .44 1.00 1.00 1.00 1.00 .86 .44 1.00 .44 1.00
1.00 1.00 1.00 .99 .98 1.00 1.00 1.00 1.00 1.00 1.00
.02 1.00 .04 1.00 1.00 1.00 .02 1.00 .83 1.00 .41
.00 .04 1.00 .32 1.00 .93 1.00 1.00 .63 1.00 1.00
.01 .00 .02 1.00 1.00 1.00 .99 1.00 1.00 1.00 .94
.00 .13 .00 .07 1.00 1.00 1.00 .32 1.00 .32 1.00
.01 .54 .02 .23 .07 1.00 1.00 1.00 .86 1.00 .91
.00 .08 .00 .04 .01 .04 1.00 .93 1.00 .93 1.00
.01 .00 .02 .95 .07 .23 .04 1.00 1.00 1.00 .94
.00 .04 1.00 .02 .00 .02 .00 .02 .63 1.00 1.00
.00 .06 .00 .05 .01 .03 .95 .05 .00 .63 .94
.00 .04 1.00 .02 .00 .02 .00 .02 1.00 .00 1.00
.02 .16 .05 .42 .14 .41 .09 .42 .05 0 .05
and rs4417206) were all located within this block and
exhibited higher values with rs498055 thanwith other2r
neighboring SNPs. (All had with rs498055.)2r 1 0.43
Comparison of these results with data in the HapMap
project indicates that the block containing rs498055 ex-
tends 419 kb and contains seven genes, LOC439999,
ALDH18A1 (MIM 138250),C10orf61, ENTPD1 (MIM
601752), hCG2023951, hCG1781136, andC10orf130.
The tree-scan analysis of 11 SNPs in the region sur-
rounding rs498055 identiﬁed signiﬁcant results across
many branches of the haplotype network. However, the
results of the conditional tests suggest that the associa-
tion observed at these branches is due to their location
in the network relative to a single branch. This branch
was signiﬁcant in both the original ( ) and thePp .0008
conditional ( ) analyses (ﬁg. 3). It is marked byPp .03
mutations creating the SNPs rs498055 and rs495998.
Discussion
Genetic variants in several biological candidate genes un-
der or near the chromosome 10 linkage peaks—including
mutations in CTNNA3 (MIM 607667), PLAU (MIM
191840), IDE (MIM 146680), and others—have been
reported to be associated with LOAD. However, none of
the associations in these candidate genes has been con-
sistently replicated (Alzheimer Disease Forum). Indeed,
our own studies in the case-control series used in the
present study showed no evidence of association with any
of these genes (Myers et al. 2004; Nowotny et al. 2005).
These ﬁndings suggest that the reported association may
be false, although it remains possible that the lack of
consistent replication may be due to type 1 error, genetic
heterogeneity, population stratiﬁcation, and/or a small ge-
netic effect confounded by sample sizes insufﬁcient to rep-
licate the initial reports. With the technology that was
available to us, we performed a broadly scaled and non-
biased genotyping program. This approach would inev-
itably be burdened by a requirement of multiple-testing
corrections to assess potential associations. To mitigate
this, we designed a two-step process in which we geno-
typed ∼1,400 SNPs in the exploratory sample set but only
69 markers in the subsequent validation sample sets. This
strategy led us to identify ﬁve SNPs, located in ﬁve genes
on chromosome 10, that are associated with LOAD. Al-
though our genotyping scan covers the entire chromo-
some 10, these signiﬁcant SNPs are located relatively close
to linkage peaks identiﬁed in other studies (Bertram et al.
2000). Our analysis included 12 SNPs in IDE, 2 SNPs in
PLAU, and 32 SNPs in CTNNA3, but none was signif-
icantly associated with LOAD (Busby et al. 2004; No-
wotny et al. 2005).
The most consistently associated marker among the
ﬁve signiﬁcant SNPs is rs498055, which is signiﬁcant in
each of the three initially tested clinical case-control se-
ries employed here, with an allelic P value of .00004 in
the meta-analysis of the three sample sets. The replica-
tion P value of .00021 is signiﬁcant even after Bonferroni
correction for 69 markers ( ), and the meta-Pp .014
analysis of these three case-control series used in the
screening paradigm is marginally signiﬁcant even after
adjustment for 1,397 SNPs ( ). The linkage sam-Pp .051
ple–derived case-control series replicates these results,
whereas the smaller combined neuropathologically con-
ﬁrmed case-control sample set is not signiﬁcant. Themeta-
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analysis of all six sample sets maintains that rs498055 is
signiﬁcantly associated with AD risk ( ).Pp .0001
The tree-scan analysis identiﬁed a single branch in
the network that is signiﬁcantly associated with LOAD.
This branch is marked by mutations at rs498055 and
rs495998. Marker rs498055 is the most signiﬁcant SNP
in the single-marker association tests (see table 1), and
rs495998 is in high LDwith rs498055 ( ) (table2r p 0.98
4). This suggests that the observed effect is a mutation
on the background shared and deﬁned by these SNPs.
It is also interesting to note that rs498055 is homopla-
sious, with mutations inferred on four different haplo-
typic backgrounds (one major and three minor haplo-
types). In some cases, the haplotype structure of a pop-
ulation allows for tests to be conducted at each branch
that is marked by a particular SNP, which provides some
evidence as to the “causal” nature of the polymorphism.
Although no association was detected at the other tran-
sitions marked by rs498055 (a result that suggests that
the SNP is not causal), the sample sizes for these tests
are too small to provide strong evidence regarding the
causality of this SNP. Inclusion of all the associated SNPs
in this region in a logistic regression analysis by use of
sequential regression (type 1) indicates that the signiﬁ-
cance derives only from LD with rs498055; that is, no
other signiﬁcant association is observed after ﬁrst in-
cluding the effect of rs498055.
Marker rs498055 is located in a gene annotated as
an RPS3A homologue in the Entrez Gene database. Al-
though the function of the RPS3A homologue is un-
known, it appears that RPS3A itself is a strong bio-
logical candidate gene for AD. It has been reported
that RPS3A mediates the interaction between BCL2 (en-
coded by BCL2 [MIM 151430]) and PARP—poly(ADP-
ribose) polymerase—(PARP1 [MIM 173870]) and that
BCL2 and RPS3A together prevent apoptosis by inhib-
iting PARP activity (Hu et al. 2000; Song et al. 2002).
Thus, RPS3A is an important player in the early phase
of apoptosis, a feature observed in AD-affected brains.
However, we have been unable to detect transcripts of
the RPS3A gene by RT-PCR in RNA from multiple tis-
sues, including brain (data not shown). This may be due
to constraints in transcript-speciﬁc primer design if a
gene has multiple paralogues, as is the case withRPS3A.
Alternatively, the annotated gene may not be expressed,
and this SNP or variants that are in LD are located in
a noncoding expressed sequence, such as a microRNA.
It is also possible that this SNP, or variants that are in
LD, modulate the transcription of neighboring genes.
The SORBS1 (MIM 605264) coding sequence is located
33.7 kb downstream from this SNP and can be consid-
ered a strong biological candidate gene. It is involved in
insulin signaling and was recently reported to be up-reg-
ulated in the hippocampus of AD-affected brains com-
pared with controls (Blalock et al. 2004). ALDH18A1
(at 91.1 Mb and in tight LD with SNPs in RPS3A) en-
codes a member of the aldehyde dehydrogenase fam-
ily, which is involved in proline biosynthesis via cata-
lyzing the conversion of L-glutamate to L-glutamate 5-
phosphate.
On the basis of the results in the combined validation
sample sets, three other markers of interest were also
identiﬁed, but they are not signiﬁcant in all three indi-
vidual samples. The power to replicate the original ob-
servation in the exploratory sample for these markers is
relatively low in each of the validation samples (table 1).
These markers are located in four different genes. PCGF5
(at 86.7 Mb) encodes polycomb group (PcG) ring ﬁnger
5, a component of a multimeric, chromatin-associated
PcG protein complex, which is involved in stable repres-
sion of gene activity. SORCS1 (MIM 606283) (at 102.7
Mb) encodes a type 1 receptor containing a Vps10p-
domain and a leucine-rich domain that is involved in
endocytosis and intracellular sorting. It is most abun-
dantly expressed in the brain (Hermey et al. 1999), and
its expression can be differentially affected by neuronal
activity (Hermey et al. 2004). hCG2039140 (at 102.9
Mb) is a predicted gene in the Celera Genome Assembly,
encoding a 41-aa polypeptide with no apparent homol-
ogy to any other known proteins. The potential relevance
of these genes with LOAD remains to be examined.
Moreover, it is possible that neighboring genes might
have a role in AD, since the signiﬁcant SNPs we iden-
tiﬁed or variants that are in LDmay affect their function.
Although the association with rs498055 was repli-
cated in the case-control series from the linkage sample,
the pedigree analyses suggest that this association did
not signiﬁcantly contribute to the original linkage signal
on chromosome 10. Although the power of this analysis
is low, it suggests that there may be more than one AD
susceptibility gene on chromosome 10.
In our screen, we did not attempt to systematically
genotype chromosome 10; rather, we used an oppor-
tunistic approach to identify functionally relevant gene-
based variants that show signiﬁcant association with AD
in at least two independently collected case-control sam-
ple sets. Therefore, we cannot exclude the majority of
nonsigniﬁcant chromosome 10 genes from those that
might contribute to the genetic risk of AD. This would
require high-density SNP genotyping incorporating an
LD-based approach to SNP selection in the case of the
common disease–common variant hypothesis and, ulti-
mately, deep resequencing of all genes, to exclude rare
pathogenic variants. However, the results outlined above
highlight ﬁve SNPs—particularly rs498055, which was
replicated in four independent case-control series—and
corresponding genes as likely AD risk factors on chromo-
some 10. These ﬁndings require functional experiments
to validate potential links of the genes and genetic varia-
tion to pathways related to disease mechanisms for AD.
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